We are live on ! Find out more
SYRE icon

Spyre Therapeutics

131 hedge funds and large institutions have $1.39B invested in Spyre Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 21 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

197% more capital inflows, than outflows

Capital inflows: $369M | Capital outflows: $124M

195% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 21

104% more call options, than puts

Call options by funds: $161K | Put options by funds: $79K

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

25% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 20

10% more funds holding

Funds holding: 119 → 131 (+12)

1.11% more ownership

Funds ownership: 100.89% → 102% (+1.1%)

Holders
131
Holders Change
+12
Holders Change %
+10.08%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
25
Increased
62
Reduced
21
Closed
20
Calls
$161​K
Puts
$79​K
Net Calls
+$82​K
Net Calls Change
+$102​K

SYRE Hedge Fund Activity: Q4 2024 in Review

131 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2024, worth a combined $1.39B — down 7.7% from $1.51B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SYRE positions and 20 closed out — a net gain of 5 holders — while 62 added to existing stakes and 21 trimmed.

The largest buyer was Driehaus Capital Management, adding an estimated $62.1M. The largest seller was Assenagon Asset Management, cutting an estimated $32.8M.

  • 131 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2024, up from 119 in Q3 2024.
  • Funds reported $1.39B of Spyre Therapeutics stock for Q4 2024, down 7.7% quarter-over-quarter.
  • 25 funds opened new Spyre Therapeutics positions in Q4 2024 and 20 closed out, a net change of +5 holders.
  • The largest Spyre Therapeutics buyer in Q4 2024 was Driehaus Capital Management, an estimated $62.1M added.
  • The largest Spyre Therapeutics seller in Q4 2024 was Assenagon Asset Management, an estimated $32.8M sold.

Based on aggregated 13F filings for Q4 2024.